Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI.

The collaboration aims to integrate these algorithms into routine eye examinations, facilitating the diagnosis of CKD.

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Tempus AI Inc. TEM during the first quarter secured ... a substantial portion of the computing costs will be covered by AstraZeneca and Pathos AI. Lefkofsky says that the model is expected to ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4% and quarterly gross profit nearly doubling, the Chicago-based health care ...

In other news, Tempus AI Inc. (NASDAQ:TEM) clinched a new $200-million deal with AstraZeneca and Pathos AI for the development of a multimodal foundation model in oncology. The total amount ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI ...

Stocks recently featured in the blog include: Tempus AI TEM, AstraZeneca AZN, iRhythm Technologies IRTC and SOPHiA GENETICS SOPH. Here are highlights from Thursday’s Analyst Blog: Tempus AI ...